E-mail: niklas.zojer@wienkav.at
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- IMPACT OF NUMBER OF PREVIOUS TREATMENT LINES AND PRE-TREATMENT WITH BORTEZOMIB OR LENALIDOMIDE ON EFFICACY OF BORTEZOMIB-BENDAMUSTINE-DEXAMETHASONE (BBD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)
- BORTEZOMIB-BENDAMUSTINE-DEXAMETHASONE (BBD) IN PATIENTS WITH RELAPSED/REFRACTORY MYELOMA AND DIFFERENT RISK PROFILES NAMELY, CYTOGENETICS, PREVIOUS EXPOSURE TO BORTEZOMIB OR TO LENALIDOMIDE
- BORTEZOMIB-BENDAMUSTINE-DEXAMETHASONE FOR TREATMENT OF RELAPSED/REFRACTORY MYELOMA
- Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between Patients and Physicians
- Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal of Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Results from a Phase II Study
- Bortezomib-Doxorubicin-Dexamethasone (BDD) in Patients with Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Final Results of a Phase II Study
- Lenalidomide and Dexamethasone for Acute Light Chain-Induced Renal Failure: Final Results of a Phase II Study
- LENALIDOMIDE-DEXAMETHASONE (LD) AS TREATMENT OF ACUTE CAST NEPHROPATHY-INDUCED RENAL FAILURE (ARF) IN MULTIPLE MYELOMA (MM). A PHASE II STUDY
- Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m2) and Triple T with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma (An Interim Analysis)
- Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study.
- Significant Activity of Lenalidomide-Dexamethasone in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure (LC-ARF)
- THALIDOMIDE-DEXAMETHASONE VERSUS MELPHALAN-PREDNISOLONE AS FIRST LINE TREATMENT IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA: AN INTERIM ANALYSIS
- Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma
- TOXICITY PROFILE DURING TREATMENT WITH BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
- Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated
